Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (601-610 of 754) with videos related to

Pageof 76
Sort By:
American Journal of Nephrology|November 3, 2025
Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and AnemiaFinnian R Mc Causland, Brian L Claggett, Petr Jarolim, et al.
Circulation Research|February 19, 2011
Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathiesDomenico D'Amario, Claudia Fiorini, Patricia M Campbell, et al.
Journal of the American Heart Association|May 31, 2017
Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes MellitusEmil Wolsk, Brian Claggett, Marc A Pfeffer, et al.
Cardiovascular Diabetology|October 13, 2020
Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trialMagnus O Wijkman, Brian Claggett, Rafael Diaz, et al.
European Journal of Heart Failure|August 19, 2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in contextEric J Velazquez, Marc A Pfeffer, John V McMurray, et al.
JACC. Heart Failure|March 14, 2021
Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF TrialKarola Jering, Brian Claggett, Margaret M Redfield, et al.
JACC. Heart Failure|March 5, 2018
Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT TrialMuthiah Vaduganathan, Brian L Claggett, Neal A Chatterjee, et al.
European Journal of Heart Failure|September 24, 2024
Sex differences in cardiac structure and function following acute myocardial infarction: Insights from the PARADISE-MI echocardiographic substudyXiaowen Wang, Maria A Pabon, Maja Cikes, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 2012
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo armHicham Skali, Julie Lin, Marc A Pfeffer, et al.
Circulation. Genomic and Precision Medicine|April 2, 2021
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular MedicineDavid Rhainds, Chris J Packard, Mathieu R Brodeur, et al.
Pageof 76

Showing results (601-610 of 754) with videos related to

Sort By:
Pageof 76
American Journal of Nephrology|November 3, 2025
Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and AnemiaFinnian R Mc Causland, Brian L Claggett, Petr Jarolim, et al.
Circulation Research|February 19, 2011
Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathiesDomenico D'Amario, Claudia Fiorini, Patricia M Campbell, et al.
Journal of the American Heart Association|May 31, 2017
Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes MellitusEmil Wolsk, Brian Claggett, Marc A Pfeffer, et al.
Cardiovascular Diabetology|October 13, 2020
Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trialMagnus O Wijkman, Brian Claggett, Rafael Diaz, et al.
European Journal of Heart Failure|August 19, 2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in contextEric J Velazquez, Marc A Pfeffer, John V McMurray, et al.
JACC. Heart Failure|March 14, 2021
Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF TrialKarola Jering, Brian Claggett, Margaret M Redfield, et al.
JACC. Heart Failure|March 5, 2018
Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT TrialMuthiah Vaduganathan, Brian L Claggett, Neal A Chatterjee, et al.
European Journal of Heart Failure|September 24, 2024
Sex differences in cardiac structure and function following acute myocardial infarction: Insights from the PARADISE-MI echocardiographic substudyXiaowen Wang, Maria A Pabon, Maja Cikes, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 2012
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo armHicham Skali, Julie Lin, Marc A Pfeffer, et al.
Circulation. Genomic and Precision Medicine|April 2, 2021
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular MedicineDavid Rhainds, Chris J Packard, Mathieu R Brodeur, et al.
Pageof 76